GlassScriptPhysician profile
Yim Ping Mo
NPI 1841653458
$5,562.51
in general payments reported to CMS, 2019-2025
21 companies · $26.59 in 2025
The $26.59 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,661 · 2022: $2,133 · 2023: $1,540 · 2024: $201 · 2025: $26.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,059.75 | 2021-2024 | Breztri, Lokelma, Farxiga |
| Novo Nordisk INC | $829.33 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $471.21 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $385.15 | 2022-2023 | |
| Amgen INC. | $373.60 | 2021-2024 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.10 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $350.69 | 2021-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $350.21 | 2021-2023 | Shingrix |
| E.R. Squibb & Sons, L.L.C. | $336.94 | 2021-2024 | Reblozyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.83 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $148.33 | 2022 | |
| Abbvie INC. | $134.70 | 2023 | |
| Scilex Pharmaceuticals INC. | $128.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $125.09 | 2023 | Xarelto |
| Pfizer INC. | $114.33 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $81.51 | 2021-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Mallinckrodt Hospital Products INC. | $38.36 | 2023 | Acthar |
| Horizon Therapeutics Plc | $38.35 | 2022-2023 | Krystexxa |
| Exact Sciences Corporation | $26.59 | 2025 | Cologuard Collection Kit |
| Mannkind Corporation | $22.47 | 2022 | |
| Dynavax Technologies Corporation | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yim Ping Mo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.